![conference banner](/images/conference-banner.jpeg)
Abstract
The European Medicines Agency (EMEA) recently issued a public statement on a possible interaction between clopidogrel and proton pump inhibitors (PPIs) and recommended that the product information for all medicines containing clopidogrel be amended to discourage concomitant use of PPIs unless absolutely necessary. This follows a prior alert issued by the United States Food and Drug Administration (FDA) earlier this year, stating that PPIs might interfere with the effectiveness of clopidogrel and that clinicians should reevaluate starting or continuing treatment with a PPI in patients taking clopidogrel. However, several experts have voiced their concern that the clopidogrel-PPI interaction has been given undue importance, given that all clinical studies suggesting this problem are observational. In this review, we critically analyze the available data and make practical suggestions for the clinician regarding appropriate use of PPIs in patients receiving clopidogrel. Based on currently available evidence, we suggest that the decision to prescribe a PPI to a patient on clopidogrel must be made on an individual patient basis balancing the gastrointestinal risk with the possible thrombotic risk and that PPIs should only be used for truly appropriate indications.
Keywords: Clopidogrel, Proton pump inhibitor, Drug interactions, Platelet inhibition, Gastroprotection
Cardiovascular & Hematological Disorders-Drug Targets
Title: Clopidogrel-Proton Pump Inhibitor Interaction: A Primer for Clinicians
Volume: 10 Issue: 1
Author(s): Christopher Allen, Steven P. Dunn, Tracy E. Macaulay and Debabrata Mukherjee
Affiliation:
Keywords: Clopidogrel, Proton pump inhibitor, Drug interactions, Platelet inhibition, Gastroprotection
Abstract: The European Medicines Agency (EMEA) recently issued a public statement on a possible interaction between clopidogrel and proton pump inhibitors (PPIs) and recommended that the product information for all medicines containing clopidogrel be amended to discourage concomitant use of PPIs unless absolutely necessary. This follows a prior alert issued by the United States Food and Drug Administration (FDA) earlier this year, stating that PPIs might interfere with the effectiveness of clopidogrel and that clinicians should reevaluate starting or continuing treatment with a PPI in patients taking clopidogrel. However, several experts have voiced their concern that the clopidogrel-PPI interaction has been given undue importance, given that all clinical studies suggesting this problem are observational. In this review, we critically analyze the available data and make practical suggestions for the clinician regarding appropriate use of PPIs in patients receiving clopidogrel. Based on currently available evidence, we suggest that the decision to prescribe a PPI to a patient on clopidogrel must be made on an individual patient basis balancing the gastrointestinal risk with the possible thrombotic risk and that PPIs should only be used for truly appropriate indications.
Export Options
About this article
Cite this article as:
Allen Christopher, Dunn P. Steven, Macaulay E. Tracy and Mukherjee Debabrata, Clopidogrel-Proton Pump Inhibitor Interaction: A Primer for Clinicians, Cardiovascular & Hematological Disorders-Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187152910790780078
DOI https://dx.doi.org/10.2174/187152910790780078 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Evaluation of MicroRNA-146 Gene Variability (rs2910164 C> G) and its Association with Increased Susceptibility to Coronary Artery Disease
MicroRNA Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Synthesis and Applications of Hydrogels in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Advances in Irrigated Tip Catheter Technology for Treatment of Cardiac Arrhythmias
Recent Patents on Cardiovascular Drug Discovery Off-Label Drug Use in Paediatrics: A World-Wide Problem
Current Drug Targets Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design The Renal Epithelial Sodium Channel: Genetic Heterogeneity and Implications for the Treatment of High Blood Pressure
Current Pharmaceutical Design Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Systems Biology Research into Cardiovascular Disease: Contributions of Lipidomics-based Approaches to Biomarker Discovery
Current Drug Discovery Technologies Speculative Considerations about Some Cardiology Enigmas
Current Cardiology Reviews Changing Paradigms in Drug Discovery: Scientific Business Intelligence™ and Workflow Solutions
Current Computer-Aided Drug Design Natural Antioxidants as Additional Weapons in the Fight against Malarial Parasite
Current Topics in Medicinal Chemistry “Cardiovascular” Drugs in Rheumatoid Arthritis: Killing Two Birds with One Stone?
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Blood Pressure and Childhood Obesity
Current Hypertension Reviews Stress Related Neuroendocrine Influences in Ovarian Cancer
Current Cancer Therapy Reviews Current Understanding of the Mechanism and Role of ROS in Angiotensin II Signal Transduction
Current Pharmaceutical Biotechnology Integrins as Therapeutic Targets for Respiratory Diseases
Current Molecular Medicine Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – an Observational Study in Germany
Current Reviews in Clinical and Experimental Pharmacology Impact of Metabolic Risk Factors on COVID-19 Clinical Outcomes: An Extensive Review
Current Cardiology Reviews